{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:45:36Z","timestamp":1760784336079},"reference-count":21,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.vaccine.2017.09.078","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T05:01:18Z","timestamp":1507784478000},"page":"6290-6296","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis"],"prefix":"10.1016","volume":"35","author":[{"given":"Ellen","family":"Strijbos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje G.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge E.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Alleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique M.","family":"van Ostaijen-ten Dam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik W.","family":"van Zwet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia M.","family":"Jol-van der Zijde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten D.","family":"van Tol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan J.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.09.078_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2017.09.078_b0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nrrheum.2011.14","article-title":"Immunology: prevention of infections in patients with autoimmune diseases","volume":"7","author":"Meyer-Olson","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.vaccine.2017.09.078_b0015","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2005.043943","article-title":"Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease","volume":"65","author":"Holvast","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2017.09.078_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/nep.12416","article-title":"Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"20","author":"Jeffs","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.vaccine.2017.09.078_b0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/08916930500285725","article-title":"Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies","volume":"38","author":"Elkayam","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.vaccine.2017.09.078_b0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/CDLI.6.3.352-355.1999","article-title":"Immunoglobulin G (IgG) Subclass Distribution and IgG1 Avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid","volume":"6","author":"Kroon","year":"1999","journal-title":"Clin Diagnos Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.09.078_b0035","doi-asserted-by":"crossref","unstructured":"Brinkman DM, Jol-Van Der Zijde CM, Ten Dam MM, Te Boekhorst PA, Rebecca ten C, Wulffraat NM, et al. Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines. J Clin Immunol 2007;27:647\u201358.","DOI":"10.1007\/s10875-007-9120-0"},{"key":"10.1016\/j.vaccine.2017.09.078_b0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2017.09.078_b0045","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2017.09.078_b0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis\u2013specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2017.09.078_b0055","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2017.09.078_b0060","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.vaccine.2017.09.078_b0065","unstructured":"Tetanus vaccine SPC. In: Biologicals B, editor; 2013."},{"key":"10.1016\/j.vaccine.2017.09.078_b0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.molimm.2013.01.012","article-title":"Effective humoral immunity against diphtheria and tetanus in patients with systemic lupus erythematosus or myasthenia gravis","volume":"54","author":"Csuka","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2017.09.078_b0075","unstructured":"Borrow R, Balmer P, Roper MH. The immunological basis for immunization series, Module 3: Tetanus, update 2006. World health organization Immunizations, vaccines and biologicals. Switzerland: World Health Organization 2007; 2006."},{"key":"10.1016\/j.vaccine.2017.09.078_b0080","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2017.09.078_b0085","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2007.077552","article-title":"The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination","volume":"67","author":"Gelinck","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2017.09.078_b0090","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/ard.2007.071878","article-title":"Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab","volume":"66","author":"Gelinck","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2017.09.078_b0095","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/jgh.13001","article-title":"Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients","volume":"30","author":"Andrade","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2017.09.078_b0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.idc.2012.06.003","article-title":"The immunosuppressed traveler","volume":"26","author":"Visser","year":"2012","journal-title":"Infect Disease Clin North Am"},{"key":"10.1016\/j.vaccine.2017.09.078_b0105","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17313312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17313312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T17:18:06Z","timestamp":1603127886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17313312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0264410X17313312"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.078","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}